CN117916376A - 信号可激活核酸复合物 - Google Patents
信号可激活核酸复合物 Download PDFInfo
- Publication number
- CN117916376A CN117916376A CN202280060504.5A CN202280060504A CN117916376A CN 117916376 A CN117916376 A CN 117916376A CN 202280060504 A CN202280060504 A CN 202280060504A CN 117916376 A CN117916376 A CN 117916376A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- acid strand
- strand
- acid complex
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218852P | 2021-07-06 | 2021-07-06 | |
| US63/218,852 | 2021-07-06 | ||
| PCT/US2022/073430 WO2023283550A1 (en) | 2021-07-06 | 2022-07-05 | Signal activatable nucleic acid complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117916376A true CN117916376A (zh) | 2024-04-19 |
Family
ID=84802044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280060504.5A Pending CN117916376A (zh) | 2021-07-06 | 2022-07-05 | 信号可激活核酸复合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250257353A1 (https=) |
| EP (1) | EP4367245A4 (https=) |
| JP (1) | JP2024525647A (https=) |
| KR (1) | KR20240095155A (https=) |
| CN (1) | CN117916376A (https=) |
| AU (1) | AU2022308843A1 (https=) |
| CA (1) | CA3224950A1 (https=) |
| IL (1) | IL309943A (https=) |
| WO (1) | WO2023283550A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014656A1 (en) | 2017-07-14 | 2019-01-17 | Han Si Ping | METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| EP3665281A4 (en) | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY |
| CN113166750B (zh) | 2018-08-10 | 2025-02-18 | 希望之城 | 可编程的条件性sirna及其用途 |
| CN116478410B (zh) * | 2023-06-20 | 2023-09-12 | 觅投克(北京)生物医学技术有限公司 | 一种菊糖修饰的聚乙烯亚胺衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696285B1 (en) * | 1998-08-25 | 2004-02-24 | Lucent Technolgies Inc. | Nanomachines fueled by nucleic acid strand exchange |
| US9029524B2 (en) * | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
| US20100112556A1 (en) * | 2008-11-03 | 2010-05-06 | Sampson Jeffrey R | Method for sample analysis using q probes |
| US8710199B2 (en) * | 2010-06-23 | 2014-04-29 | California Institute Of Technology | Signal activated molecular delivery |
| US9725715B2 (en) * | 2011-06-23 | 2017-08-08 | California Institute Of Technology | Signal activatable constructs and related components compositions methods and systems |
| WO2013142735A1 (en) * | 2012-03-21 | 2013-09-26 | California Institute Of Technology | Targeting domain and related signal activated molecular delivery |
| US9856472B2 (en) * | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
| WO2019033083A1 (en) * | 2017-08-10 | 2019-02-14 | City Of Hope | CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| EP3665281A4 (en) * | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY |
| CN113166750B (zh) * | 2018-08-10 | 2025-02-18 | 希望之城 | 可编程的条件性sirna及其用途 |
-
2022
- 2022-07-05 CA CA3224950A patent/CA3224950A1/en active Pending
- 2022-07-05 KR KR1020247004152A patent/KR20240095155A/ko active Pending
- 2022-07-05 US US18/575,487 patent/US20250257353A1/en active Pending
- 2022-07-05 CN CN202280060504.5A patent/CN117916376A/zh active Pending
- 2022-07-05 EP EP22838546.4A patent/EP4367245A4/en active Pending
- 2022-07-05 WO PCT/US2022/073430 patent/WO2023283550A1/en not_active Ceased
- 2022-07-05 JP JP2024500651A patent/JP2024525647A/ja active Pending
- 2022-07-05 AU AU2022308843A patent/AU2022308843A1/en active Pending
- 2022-07-05 IL IL309943A patent/IL309943A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4367245A4 (en) | 2025-07-02 |
| WO2023283550A1 (en) | 2023-01-12 |
| IL309943A (en) | 2024-03-01 |
| CA3224950A1 (en) | 2023-01-12 |
| EP4367245A1 (en) | 2024-05-15 |
| JP2024525647A (ja) | 2024-07-12 |
| KR20240095155A (ko) | 2024-06-25 |
| AU2022308843A1 (en) | 2024-02-01 |
| US20250257353A1 (en) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6236498B2 (ja) | 非対称性干渉rnaの組成物およびその使用 | |
| CN117916376A (zh) | 信号可激活核酸复合物 | |
| CN118202048A (zh) | 条件可激活核酸复合物 | |
| JP2022528487A (ja) | C9orf72のオリゴヌクレオチドベースの調節 | |
| JP2014097072A5 (https=) | ||
| US20240409933A1 (en) | Condition-activatable nucleic acid constructs and their uses for treating neurological diseases | |
| KR102701681B1 (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 | |
| WO2023230465A1 (en) | Antisense oligonucleotides | |
| CN118414428A (zh) | 条件可激活核酸构建体及其用于治疗神经疾病的用途 | |
| HK40051253A (en) | Compositions of asymmetric interfering rna and uses thereof | |
| Schmitz et al. | Pharmacokinetics Of Nucleic‐Acid‐Based Therapeutics | |
| HK1228948A1 (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1217349B (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1148534B (en) | Compositions of asymmetric interfering rna and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |